scholarly journals Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4.

1993 ◽  
Vol 91 (1) ◽  
pp. 88-93 ◽  
Author(s):  
N I Obiri ◽  
G G Hillman ◽  
G P Haas ◽  
S Sud ◽  
R K Puri
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Growth ◽  
Tumor Cell ◽  
Renal Cell ◽  
Carcinoma Cells ◽  
Interleukin 4 ◽  
Tumor Cell Growth ◽  
Human Renal Cell Carcinoma ◽  
High Affinity

scholarly journals Cellular Polarity Correlates with Vimentin Distribution, but not to Keratin, in Human Renal Cell Carcinoma Cells in vitro.

1994 ◽  
Vol 19 (3) ◽  
pp. 115-121
Author(s):  
Mayumi Sasaki ◽  
Norimasa Sawada ◽  
Hideki Chiba ◽  
Noriomi Miyao ◽  
Taiji Tsukamoto ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Carcinoma Cells ◽  
Cellular Polarity ◽  
Human Renal Cell Carcinoma

Influence of Growth Factors on in Vitro Invasiveness and Type IV Collagenolysis of Human Renal Cell Carcinoma Cells

1994 ◽  
Vol 151 (1) ◽  
pp. 223-226 ◽  
Author(s):  
Noriyuki Otani ◽  
Taiji Tsukamoto ◽  
Naoya Masumori ◽  
Ikuo Saiki ◽  
Junya Yoneda ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factors ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Carcinoma Cells ◽  
Human Renal Cell Carcinoma ◽  
Type Iv ◽  
In Vitro Invasiveness

scholarly journals Inhibition of MicroRNA-381 Promotes Tumor Cell Growth and Chemoresistance in Clear-Cell Renal Cell Carcinoma

2019 ◽  
Vol 25 ◽  
pp. 5181-5190 ◽  
Author(s):  
Yunhui Chan ◽  
Yipeng Yu ◽  
Gang Wang ◽  
Changlin Wang ◽  
Daming Zhang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Growth ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Tumor Cell Growth ◽  
Cell Renal Cell Carcinoma

scholarly journals Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Margherita Passariello ◽  
Anna Morena D’Alise ◽  
Annachiara Esposito ◽  
Cinzia Vetrei ◽  
Guendalina Froechlich ◽  
...  
Keyword(s):  
Cell Growth ◽  
Tumor Cell ◽  
Cancer Cells ◽  
Mapk Pathway ◽  
Immune Checkpoints ◽  
Tumor Cell Growth ◽  
Potent Effect ◽  
High Affinity

Abstract The novel antibody-based immunotherapy in oncology exploits the activation of immune system mediated by immunomodulatory antibodies specific for immune checkpoints. Among them, the programmed death ligand-1 (PD-L1) is of particular interest as it is expressed not only on T-cells, but also on other immune cells and on a large variety of cancer cells, such as breast cancer cells, considering its high expression in both ErbB2-positive and Triple Negative Breast Cancers. We demonstrate here that PD-L1_1, a novel anti-PD-L1 T -cell stimulating antibody, inhibits PD-L1-tumor cell growth also by affecting the intracellular MAPK pathway and by activating caspase 3. Similar in vitro results were obtained for the first time here also with the clinically validated anti-PD-L1 mAb Atezolizumab and in vivo with another validated anti-mouse anti-PD-L1 mAb. Moreover, we found that two high affinity variants of PD-L1_1 inhibited tumor cell viability more efficiently than the parental PD-L1_1 by affecting the same MAPK pathways with a more potent effect. Altogether, these results shed light on the role of PD-L1 in cancer cells and suggest that PD-L1_1 and its high affinity variants could become powerful antitumor weapons to be used alone or in combination with other drugs such as the anti-ErbB2 cAb already successfully tested in in vitro combinatorial treatments.

Sign in / Sign up

Export Citation Format

Share Document